Key result
Jusvinza demonstrates ~10-fold higher binding affinity for apolipoprotein A-I vs wild-type peptide.
Answers are grounded in this paper and cite their sources.
CIGB-814 interacts specifically with apolipoprotein A-I, providing mechanistic insight into its immunomodulatory and metabolic effects and suggesting potential applications in metabolic diseases.
Jusvinza is an immunomodulatory pharmaceutical drug developed for the treatment of rheumatoid arthritis. Its active ingredient is an altered peptide ligand-derived from a T-cell epitope of the human 60-kDa heat shock protein-referred to as CIGB-814. Jusvinza has also proven effective in reducing hyperinflammation in COVID-19. However, molecular targets of CIGB-814 in patients remain undefined, and this study is aimed at identifying specific plasma proteins that interact with CIGB-814. Affinity chromatography and mass spectrometry analysis revealed apolipoprotein A-I as a CIGB-814-binding partner. Interestingly, no apolipoprotein A-I bands were detected in the affinity matrix of the wild-type peptide (designated as E18-3). In this context, it was relevant to analyze how the substitution of Asp18 with Leu-used to design CIGB-814 from the wild-type peptide-confers its ability to bind apolipoprotein A-I. Docking studies predicted the N-terminal domain of apolipoprotein A-I as the most likely region for peptide interaction and suggested a strong connection between CIGB-814 and apolipoprotein A-I. Further validation by molecular dynamics simulations suggests that CIGB-814 may enhance the flexibility of structural areas in apolipoprotein A-I critical for high-density lipoproteins assembly. Additionally, an affinity enzyme-linked immunosorbent assay (ELISA) confirmed that apolipoprotein A-I has a tenfold greater affinity for CIGB-814 compared to the wild-type peptide. These integrated experimental and computational findings demonstrate that a single residue substitution is critical for apolipoprotein A-I recognition. In addition, this study provides mechanistic insight into CIGB-814 immunomodulatory and metabolic effects, expanding the therapeutic potential of Jusvinza to metabolic diseases associated with lipid homeostasis imbalance.
No takes yet. Share an insight, caveat, or question.
Rosales et al. (2026) studied this question. Jusvinza (CIGB-814) vs. Wild-type peptide (E18-3) was evaluated on Binding affinity to apolipoprotein A-I. Jusvinza (CIGB-814) demonstrated a 10-fold greater binding affinity for apolipoprotein A-I compared to the wild-type peptide, providing mechanistic insight into its immunomodulatory effects.
Synapse has enriched 10 related papers. Consider them for comparative context: